The quality of reports of randomized trials in multiple sclerosis: a review
|
|
- Sophia Lee
- 6 years ago
- Views:
Transcription
1 444327MSJ / Signori et al.multiple Sclerosis Journal 2012 Topical Review MULTIPLE SCLEROSIS JOURNAL MSJ The quality of reports of randomized trials in multiple sclerosis: a review Multiple Sclerosis Journal 18(6) The Author(s) 2012 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: / msj.sagepub.com Alessio Signori, Alice Baccino and Maria Pia Sormani Abstract Randomized clinical trials (RCT) in multiple sclerosis (MS) have a recent tradition, but their number has been exponentially increasing since the first study detecting the efficacy of a disease modifying drug in MS. To examine the methodological details of reports of RCT in MS, we extracted from five leading journals all the reports of RCT published between 1993 and Trial reports were compared for different periods ( , , ) for a set of indicator variables reflecting methodological quality (including details about randomization and blinding, statistical methods, results reporting, subgroup analyses). Fifty-three reports were included in the analysis. All of the methodological items indicated an improvement over time in the quality of reporting, the main weaknesses being frequent and inappropriate use of significance testing for assessing baseline imbalances and the statistical approach to subgroup analysis. A complete and transparent reporting of trial methodology is becoming even more important in an era when new design strategies are required for the feasibility of future trials in MS. Keywords Randomized clinical trials, CONSORT statement, clinical trials methodology, subgroup analysis Date received: 9th February 2012; revised: 29th February 2012; 11th March 2012; accepted: 13th March 2012 Introduction The first positive trial assessing the efficacy of a disease modifying drug (DMD) in multiple sclerosis (MS) is dated in fixing at that year the start of the era of randomized clinical trials (RCT) in MS, much later than, for example, oncology which boasts a long tradition in RCT since the late 1950s. Since that year, many RCT have been conducted in MS and a standard methodology has been consolidated ranging from phase II placebo-controlled trials, typically lasting 6 months with Magnetic Resonance Imaging (MRI) endpoints, to phase III placebo-controlled trials lasting 1 2 years with relapse or disability progression endpoints. This process has brought to the market new drugs as alternatives to Interferon, and other therapies will become available in the near future. So we have entered a new era of RCT in MS: since patients are enrolled in trials which are more and more benign and the use of placebo has become ethically questionable 2 new design strategies are required to handle this evolution, and a large effort is devoted to study, among other strategies, the validation of surrogate outcomes 3,4 and the application of adaptive designs. 5,6 Therefore, after about 20 years of RCT history in MS, the aim of this paper is to review the quality of RCT in MS reports from 1993 to In this last decade, the quality of RCT reporting has in general constantly improved, with many journals having statistical refereeing and clearer guidelines to authors. The Consolidated Standards of Reporting Trials (CONSORT) Statement, first published in and revised in and provides recommendations for authors regarding how to prepare reports of trial findings. In this paper we assessed the methodology of RCT reports in MS using indicators of quality based mainly on the explicit reporting of details of trial design and conduction, statistical analysis and the display of results. Material and methods We searched reports of RCT in MS published between 1993 and July 2010 in The Lancet, Lancet Neurology, Annals of Neurology, Neurology and The New England Department of Health Sciences, University of Genoa, Italy Corresponding author: Maria Pia Sormani, Department of Health Sciences (DISSAL), University of Genoa, Via Pastore 1, Genoa, 16132, Italy. mariapia.sormani@unige.it
2 Signori et al. 777 Journal of Medicine. We screened electronic databases (Ovid MEDLINE (1993 July 2010), PubMed (1993 July 2010), the Cochrane Central Register of Controlled Trials (1993 July 2010) to identify trials fulfilling the following inclusion criteria: randomized, phase II or phase III, placebo or active-controlled trials in MS, assessing the efficacy of DMD of any class. Reviews, observational studies and secondary publications were excluded. Two researchers (AB and AS) independently extracted data relevant for the analysis and any discrepancies were checked by a third assessor (MPS) and resolved by discussion. MS type, trial phase, number of centers, treatment arms, sample size and follow-up length were extracted as general items. The presence of the term randomized in the title, systems to implement randomization and method to generate randomization lists, blinding methodology, explicit definition of the primary outcome, intention to treat (ITT) analysis and details about calculation of sample size were extracted as methodological items. The presence of a flow diagram, details on patients lost to follow-up, reporting and comparison of baseline characteristics between randomized group and possible imbalances noticed, covariate adjustment for primary outcome (pre-planned or not) and which analysis (unadjusted or adjusted) received more emphasis were collected as items related to presentation of results. The number and proportion (%) of trials reporting different items of the CONSORT statement were reported. Years of publication were categorized in three classes, as , , SPSS (v.18; IBM Corporation) was used for computation. Results A total of 288 studies were screened. Of these, 226 were excluded mainly because they were solely observational studies or they were focused on symptomatic drugs. Among the remaining 62 papers, nine were excluded after reading the full articles (Figure 1) and 53 trials were finally included: 23 published in Neurology, 10 in The Lancet, 9 in The New England Journal of Medicine, 7 in Lancet Neurology and 4 in Annals of Neurology. Seventeen studies were published in , 17 in and the remaining 19 studies in A table listing all of the studies included in this review is reported in the Supplementary Material. General characteristics Table 1 reports the general characteristics of the included studies: 29 (54.7%) were on relapsing remitting (RR) MS patients, 8 (15.1%) on secondary progressive (SP) MS patients, 4 (7.5%) on clinically isolated syndrome (CIS) subjects and the remaining 12 (22.6%) on a mixture of RR, SP and primary progressive (PP) MS patients; 23 studies (43.4%) were phase II, 30 (56.6%) were phase III studies. The vast majority of RCT in MS was sponsored by Figure 1. Flowchart of the procedure for the selection of reports of clinical. industry: in our sample 42 (79%) trials were sponsored by a single company, 7 (13%) had a mixed funding (industry and academia or MS societies) and only 3 (6%) were sponsored by non-profit institutions. The median number of patients enrolled was 297 (range ) with a median follow-up of two years (range 6 36 months). Just four trials were monocentric, and the median number of centers involved in multicenter studies was 32 (range 1 198). The number of centers involved was significantly higher in (median=50) as compared to (median=37) and (median=11, p=0.001, test for trend). Twenty-eight trials (52.8%) had two arms, 22 trials (41.5%) had three arms, two trials (3.8%) had four arms and one trial (1.9%) had five arms. Overall 44 trials (83%) were placebo-controlled. Primary outcomes were MRI outcomes (41.5%), relapses (26.4 %) or disability (22.6%); other outcomes were both relapses and disability (7.5%) or relapses and MRI (1.9%). Methodological characteristics Table 2 shows information collected on methodological items. The term randomized is reported after 2001 (55.6% of trials) slightly more frequently than in the period (35.3%, p= 0.28). Most of the trials (about 83%) did not report the systems of allocation concealment and, if quoted, the interactive voice responder resulted the most adopted method (13.2%). The statistical method used to generate the randomization list was specified in 43 trials (81.1%), with block randomization as the most used method (81.4%). In 25 out of the 49 multicenter studies (51%), randomization was balanced for center. Among the 17 trials for which a randomization balanced for baseline covariates was done, seven studies involved
3 778 Multiple Sclerosis Journal 18(6) Table 1. General characteristics of randomized trials. Total (n=53) (n=19) Type of multiple sclerosis (n, %) RR 29 (54.7%) 8 (47.1%) 8 (47.1%) 13 (68.4%) SP 8 (15.1%) 4 (23.5%) 3 (17.6%) 1 (5.3%) CIS 4 (7.5%) 2 (11.8%) 1 (5.9%) 1 (5.3%) RR-SP-PP 12 (22.6%) 3 (17.6%) 5 (29.4%) 4 (21.1%) Phase of trial (n, %) II 23 (43.4%) 7 (41.2%) 5 (29.4%) 11 (57.9%) III 30 (56.6%) 10 (58.8%) 12 (70.6%) 8 (42.1%) Sample size (median, IQR) 297 ( ) 251 (97 372) 318 ( ) 306 ( ) Centres (median, IQR) 32 (11 57) 11 (7 22) 37 (19 92) 50 (32 80) Follow-up length (median, IQR) 24 (12 24) 24 (9 26) 24 (12 24) 18 (12 24) Number of treatments (n, %) Two 28 (52.8%) 11 (64.7%) 9 (53%) 8 (42.1%) Three 22 (41.5%) 6 (35.3%) 8 (47%) 8 (42.1%) More than three 3 (5.7%) (15.8%) Placebo (n, %) 44 (83%) 17 (100%) 13 (76.5%) 14 (73.7%) CIS: clinically isolated syndrome; IQR: interquartile range; PP: primary progressive; RR: relapsing remitting; SP: secondary progressive only one baseline characteristic and a maximum of four features was balanced for. The baseline characteristics most used for adjustment were age, sex and Expanded Disability Status Scale (EDSS). In the majority of trials (90.6%) a double-blind procedure was implemented, with only one study conducted without any method of blinding. Among blinded trials, 49 (94.2%) reported details on who was blinded and in 31 (59.6%) details on how blinding was achieved were shown. Details about calculation of sample size were reported in 44 trials (83%). Primary outcome was predefined in all but two trials, both run in the period Thirty-four trials (64.2%) were positive trials, with a significant treatment effect. In 42 trials (79.2%) the ITT principle was adopted for data analysis, with an increase in more recent trials ( : 88.9%) as compared to older studies ( %, p=0.02). Trial reporting Table 3 gives information about the reports results sections. Eleven trials (20.8%) did not report any CONSORT diagram, eight of which were between 1993 and 2001 (p=0.002 for the comparison vs ). The number of levels of the diagrams increased from a median of four (range 0 7) in the period to a median of six (range 0 14, p=0.009). Almost all trials (52/53) reported information on the number of patients lost to follow-up, with 50 trials (94.3%) also reporting details about reasons for the loss to follow-up. All trials showed a table of baseline characteristics by treatment allocation. The number of baseline features varied widely with a median of 10 features and a maximum of 22 features. About half of the trials (28/53, 52.8%) assessed imbalances between treatment groups by significance tests. Imbalance, based on p<0 05, was claimed in six trials, for a total of eight significant baseline differences, which is 3% of 274 identifiable significance tests. The use of statistical tests to evaluate imbalances of baseline characteristics has not decreased in more recent years (p for heterogeneity=0.22, Table 3). Thirty-nine trials (73.6 %) analyzed primary outcomes with adjustment for some covariates and in 35.9% of trials adjustment was pre-planned. The number of covariates used to adjust for was never higher than 6 and adjustment for 2 4 covariates was the most frequent case. The majority of studies (76.9%) using a covariate adjustment for the primary outcome reported just the adjusted results and only in 15.4% of trials both unadjusted and adjusted results were shown; none of these trials found any difference between adjusted and unadjusted results. Correction for the center effect was applied to 20 (52.6%) out of the 37 multicenter trials including a covariate adjustment. Covariates frequently included into the main analysis were baseline EDSS score, previous years relapses or baseline MRI activity. The statistical methods most widely used were the Cox proportional hazard model or the log-rank test for time to progression of disability; the analysis of covariance (ANCOVA) was used for the number of MRI lesions or the rate of clinical relapses. In more recent years this model was replaced by generalized linear models, as Poisson regression (for relapse rate) and Negative Binomial regression (for MRI lesions). Fifteen trials (28.3%) included subgroup analysis in the principal report while other three trials had a subgroup analysis performed and published in separate papers. Among these 15 trials, four (26.7%) presented subgroup results without statistical tests, eight (53.3%) reported the p-values
4 Signori et al. 779 Table 2. Reporting of methodological characteristics. Total (n=53) (n=19) Randomized stated in title Yes 26 (49.1%) 6 (35.3%) 9 (53%) 11 (57.9%) No 27 (50.9%) 11 (64.7%) 8 (47%) 8 (42.1%) Method of allocation concealment Defined 9 (17%) 0 6 (35.3%) 3 (15.8%) Undefined 44 (83%) 17 (100%) 11 (64.7%) 16 (84.2%) Method to generate random sequence Specified 43 (81.1%) 10 (58.8%) 17 (100%) 16 (84.2%) Block randomization 35 (66%) 8 (47%) 13 (76.5%) 14 (73.7%) Minimization 6 (11.3%) 1 (5.9%) 3 (17.6%) 2 (10.5%) Other 2 (3.8%) 1 (5.9%) 1 (5.9%) 0 Unspecified 9 (16.9%) 7 (41.2%) 0 3 (15.8%) Randomization balanced for center 1 Yes 25 (51%) 6 (42.9%) 8 (50%) 11 (57.9%) No 14 (28.6%) 1 (7.1%) 8 (50%) 5 (26.3%) Unspecified 10 (20.4%) 7 (50%) 0 3 (15.8%) Randomization balanced for other baseline factors Yes 17 (32.1%) 3 (17.7%) 7 (41.2%) 7 (36.8%) No 24 (45.3%) 5 (29.4%) 10 (58.8%) 9 (47.4%) Unspecified 12 (22.6%) 9 (52.9%) 0 3 (15.8%) Blinding Double-blind 48 (90.6%) 17 (100%) 15 (88.2%) 16 (84.2%) Single blind 4 (7.5%) 0 2 (11.8%) 2 (10.5%) Details reported 49 (94.2%) 14 (82.4%) 17 (100%) 18 (100%) Details not reported 3 (5.8%) 3 (17.6%) 0 0 No blinding 1 (1.9%) (5.3%) Blinding - how achieved Reported 31 (59.6%) 8 (47.1%) 11 (64.7%) 12 (66.7%) Not reported 21 (40.4%) 9 (52.9%) 6 (35.3%) 6 (33.3%) Sample size calculation Yes 44 (83%) 12 (70.6%) 15 (88.2%) 17 (89.5%) No 9 (17%) 5 (29.4%) 2 (11.8%) 2 (10.5%) Primary outcome definition Yes 51 (96.2%) 15 (88.2%) 17 (100%) 19 (100%) No 2 (3.8%) 2 (11.8%) 0 0 Intention to treat Yes 38 (71.7%) 10 (58.8%) 14 (82.4%) 14 (73.7%) No 15 (28.3%) 7 (41.2%) 3 (17.6%) 5 (26.3%) 1 Excluded four studies run in a single center. of comparison between drugs in each subgroup while only three (20%) performed an interaction analysis to test for heterogeneity of treatment effect between the subgroups. All reports did subgroup analysis on the primary outcome of the study while in seven studies (46.7%) this was done on more than one outcome. Six reports (40%) claimed features from subgroup analysis on abstract or conclusions. Discussion The clinical trial scenario in MS has been rapidly changing in these last years. The advent of new effective therapies has made the use of placebo unethical, 2 at least in trials lasting more than six months. Methodological research in MS is focusing on the search for better clinical outcomes and valid surrogate markers to investigate the efficacy of new drugs with enough power. With this background, in this review we give a picture of the state of the art of methodology of RCT in MS, focusing on the quality of reporting in five leading journals. A detailed documentation of randomization methods was lacking in the first MS trial reports, but improved after the publication of the CONSORT statement in Methods used to generate the random sequence, details
5 780 Multiple Sclerosis Journal 18(6) Table 3. Reporting of results. Total (n=53) (n=19) Consort flow diagram Included 42 (79.2%) 9 (52.9%) 16 (94.1%) 17 (89.5%) Not included 11 (20.8%) 8 (47.1%) 1 (5.9%) 2 (10.5%) Loss to follow-up Reported 52 (98.1%) 16 (94.1%) 17 (100%) 19 (100%) Not reported 1 (1.9%) 1 (5.9%) 0 0 Statistical test for difference at baseline Yes 26 (49.1%) 8 (47.1%) 11 (64.7%) 7 (36.8%) Imbalance noted 6 (23.0%) 0 3 (50.0%) 3 (50.0%) No 27 (50.9%) 9 (52.9%) 6 (35.3%) 12 (63.2%) Covariate adjustment for primary outcome analysis Yes 39 (73.6%) 11 (64.7%) 12 (70.6%) 16 (84.2%) No 14 (26.4%) 6 (35.3%) 5 (29.4%) 3 (15.8%) Pre-planned adjustment 1 Yes 14 (35.9%) 2 (18.2%) 6 (50%) 6 (37.5%) No 25 (64.1%) 9 (81.8%) 6 (50%) 10 (62.5%) Analysis more emphasized 1 Unadjusted 3 (7.7%) 1 (9.1%) 2 (16.7%) 0 Adjusted 30 (76.9%) 9 (81.8%) 6 (50%) 15 (93.8%) Either 6 (15.4%) 1 (9.1%) 4 (33.3%) 1 (6.3%) 1 Considering only trials with covariate adjustment. about blinding, details about the balancing of randomization, assumptions for sample size calculation and application of the ITT analysis have all featured in improved documentation after This improvement can be imputed to the editorial policy of medical journals that, with the endorsement of the CONSORT statement, both helps authors in providing the clarity needed by readers wishing to assess a trial s validity, and also forces researchers and sponsors to routinely implement the basic procedures of good methodology of RCT. A questionable practice largely adopted is the use of significance tests for detecting baseline differences. The null hypothesis of no differences between the treatment arms is true by definition, since the randomization procedure guarantees that any baseline differences are due to chance alone. About half of the trials do such significance tests and this practice does not decrease in recent years; on the other hand, usually no information is given on whether baseline factors are associated with outcome, a more interesting insight than the focus on significant differences that are by chance. Our 3% rate of significant baseline comparisons is slightly lower than in earlier surveys with a 4 6% rate and is consistent with the rate of 5% of such tests expected to reach p<0 05. The statistical issues related to subgroup analysis in RCT are well known including the concept that the reliance on subgroup p values is misleading. Nevertheless the use of interaction tests to assess the heterogeneity of treatment effect across different subgroups, the correct approach, is still underused. Subgroup analysis reflects the scientifically important issue that the treatment may have really different effects according to certain baseline characteristics. However, if the overall treatment effect is significant, some subgroups will and some will not show significant differences depending on chance and the smallness of subgroups. An example is the subgroup analysis of the CHAMPS study, 15 published in a companion paper. In the abstract the authors stated, Intramuscular Interferonβ-1a initiated at a first demyelinating attack delayed clinically definite MS in monofocal patients (P=0.0013), patients with or without gadolinium enhancing lesions (P=0.0007, P=0.0405) and patients with at least nine T2 lesions at baseline (P=0.0044). This sentence suggests that the drug delayed clinically definite MS just in the indicated subgroups. As for patients classified according to their number of baseline T2 lesions, in the results we find that over 2 years, the unadjusted Hazard Ratio (HR) was 0.50 (95% Confidence Interval (CI) ; P=0.1700) for patients with fewer than nine T2 lesions and 0.53 (95%CI ; P=0.0044) for patients with nine or more T2 lesions. So the treatment effect was pretty much the same in the two subgroups, but it was non-significant in patients with fewer than nine T2 lesions because their group was small (90 subjects), while it was significant for patients with nine or more T2 lesions who were more numerous (286 subjects). The correct approach, based on an interaction test, would have compared the HRs (0.50 vs. 0.53), indicating a lack of evidence that the intervention s effect (significant on the whole
6 Signori et al. 781 group) depended on the number of baseline T2 lesions. Subgroup analysis constitutes additional data usually not appearing in the first report that would be of interest for MS specialized journals. It must be noted that, since interaction tests commonly lack statistical power in single trials, the combination of individual patients data in meta-analyses would be crucial to detect subgroup effects. Meta-analyses pooling individual-patient data from different RCT have never been performed in MS research, due to the companies reluctance to combine their data. MS specialized journals should promote the publication of such kind of pooled analyses. Since most of the RCT in MS are fully or partially sponsored by industry (92% of those included in our analysis) it is not possible to assess the impact of the funding source on the quality of reporting. Otherwise, while industry-funded research largely resulted associated with increased likelihood of pro-industry results, there are conflicting results on the limited data about the association of industry funding with methodological quality, with some studies indicating even a higher quality (probably associated with the greater financial resources) compared to non-industry funded trials In conclusion, reporting of several important aspects of trial methods has improved since The editorial policy of medical journals has driven this improvement and should continue to enrich the guidelines for authors, covering also technical aspects (e.g. the use of interaction test is required for subgroup analysis ) whose application will end up to educating authors to the adoption and reporting of correct procedures. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest MPS has received consulting fees or honoraria from Biogen IDEC, Merck Serono, Actelion, Synthon, Allozyne. AS and AB have no conflicts of interest. References 1. The IFNB Multiple Sclerosis Study Group. Interferon betalb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43(4): Polman CH, Reingold SC, Barkhoff, et al. Ethics of placebocontrolled clinical trials in multiple sclerosis: a reassessment. Neurology 2008; 70: Sormani MP, Bonzano L, Roccatagliata L et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009; 65: Sormani MP, Bonzano L, Roccatagliata L et al. Surrogate endpoints for EDSS worsening in multiple sclerosis. A metaanalytic approach. Neurology 2010; 75: Friede T, Parsons N, Stallard N, et al. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis. Stat Med 2011; 30 (13): Chataway J, Nicholas R, Todd S, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler 2011; 17: Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996; 276: Moher D, Schulz KF and Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: Schulz KF, Altman DG and Moher D, for the CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Ann Int Med 2010; 152: Assmann SF, Pocock SJ, Enos LE et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355: Senn S. Testing for baseline balance in clinical trials. Stat Med 1994; 13: Altman DG. Comparability of randomised groups. Statistician 1985; 34: Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. JAMA 1991; 266: Pocock SJ, Hughes MD and Lee RJ. Statistical problems in the reporting of clinical trials: a survey of three medical journals. N Engl J Med 1987; 317: O Connor P, Kinkel RP and Kremenchutzky M. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria Mult Scler 2009; 15: Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant proindustry findings in medical and surgical randomized trials. CMAJ 2004; 170: Montgomery JH, Byerly M, Carmody T, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials 2004; 25: Yaphe J, Edman R, Knishkowy B, et al. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract 2001; 18: Thomas O, Thabane L, Douketis J, et al. Industry funding and the reporting quality of large long-term weight loss trials. Int J Obes (Lond) 2008; 32: Rios LP, Odueyungbo A, Moitri MO, et al. Quality of reporting of randomized controlled trials in general endocrinology literature. J Clin Endocrinol Metab 2008; 93: Khan NA, Lombeida JI, Singh M, et al. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. Arthritis Rheum doi: /art [In press].
There are currently 4 US Food and Drug
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationBeta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32)
Public slides part 1 (Redacted) Beta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32) 3 rd Appraisal Committee meeting Committee B, 16 th November 2017 Previous Appraisal
More informationTechnology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320
Dimethyl fumarate ate for treating relapsing-remitting multiple sclerosis Technology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320 NICE 2018. All rights reserved. Subject to Notice
More informationPublished on The YODA Project (
Principal Investigator First Name: Mirjana Last Name: Stanic Benic Degree: MD Primary Affiliation: UHC Rijeka E-mail: mirji.stanic@gmail.com Phone number: 00385992367664 Address: Kresimirova 42e Kresimirova
More informationIndirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee
Indirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee 2009 CADTH Symposium April 6, 2009, Ottawa, ON Presentation Outline Background on indirect
More informationScientific journal editor core competencies
Scientific journal editor core competencies My disclosures Founding editor-in-chief, Systematic Reviews On the editorial board of several biomedical journals BMC Medicine Advisory member International
More informationSession 4: Statistical considerations in confirmatory clinical trials II
Session 4: Statistical considerations in confirmatory clinical trials II Agenda Interim analysis data monitoring committees group sequential designs Adaptive designs sample size re-estimation Phase II/III
More informationHow To Design A Clinical Trial. Statistical Analysis. Gynecologic Cancer InterGroup
How To Design A Clinical Trial Statistical Analysis Andrew Embleton PhD student/medical Statistician MRC Clinical Trials Unit at UCL At what points do you need to consider statistics? At what points do
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationThe CONSORT Statement II
L'Integrità della Ricerca Biomedica nell era dell'evidence-based Health Care Istituti Ortopedici Rizzoli Bologna, 23 novembre 2001 Consolidated olidated standards of Reporting Trial revised The CONSORT
More informationMissing Data Handling in Non-Inferiority & Equivalence Trials
Missing Data Handling in Non-Inferiority & Equivalence Trials A systematic review Brooke A Rabe Graduate Interdisciplinary Program in Statistics The University of Arizona, Tucson, USA PSI s Pharmaceutical
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 April 2011 COPAXONE 20 mg/ml, solution for injection, pre-filled syringe B/28 (CIP code: 363 840-1) Applicant: SANOFI-AVENTIS
More informationRESEARCH. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed
The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed Sally Hopewell, senior research fellow, 1 Susan Dutton, senior medical statistician, 1 Ly-Mee
More informationIntroducing MN-166 Multiple Sclerosis. July 9, 2008
Introducing MN-166 A New Treatment Paradigm for Multiple Sclerosis July 9, 2008 MediciNova, Inc. 2008 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute
More informationRESEARCH PAPER. Multiple sclerosis
Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10. 1136/ jnnp- 2016-314843). For numbered affiliations see end of article. Correspondence to
More informationRESEARCH PAPER. Multiple sclerosis
Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10. 1136/ jnnp- 2016-314843). For numbered affiliations see end of article. Correspondence to
More informationJNNP Online First, published on December 30, 2016 as /jnnp Multiple sclerosis
Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ jnnp-2016-314843). For numbered affiliations see end of article. Correspondence to Professor
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (Final) GLATIRAMER ACETATE (GLATECT PENDOPHARM) Indication: Relapsing-Remitting Multiple Sclerosis RECOMMENDATION: The CADTH
More informationHeterogeneity Random and fixed effects
Heterogeneity Random and fixed effects Georgia Salanti University of Ioannina School of Medicine Ioannina Greece gsalanti@cc.uoi.gr georgia.salanti@gmail.com Outline What is heterogeneity? Identifying
More informationAubagio (teriflunomide tablets) Policy Number: Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018
Aubagio (teriflunomide tablets) Policy Number: 5.01.614 Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationQuality of reporting of clinical non-inferiority and equivalence randomised trials - update and extension
Schiller et al. Trials 2012, 13:214 TRIALS RESEARCH Open Access Quality of reporting of clinical non-inferiority and equivalence randomised trials - update and extension Petra Schiller 1*, Nicole Burchardi
More informationBayer Corporate Policy: Global Publications Deriving from Clinical Studies in Humans
Bayer Corporate Policy: Global Publications Deriving from Clinical Studies in Humans Overview The key aspects of this Global Publication Policy are commitment to publish; consistent application of authorship
More informationDisclaimer This presentation expresses my personal views on this topic and must not be interpreted as the regulatory views or the policy of the FDA
On multiplicity problems related to multiple endpoints of controlled clinical trials Mohammad F. Huque, Ph.D. Div of Biometrics IV, Office of Biostatistics OTS, CDER/FDA JSM, Vancouver, August 2010 Disclaimer
More informationShort Course: Adaptive Clinical Trials
Short Course: Adaptive Clinical Trials Presented at the 2 Annual Meeting of the Society for Clinical Trials Vancouver, Canada Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical
More informationMethodological characteristics of academic clinical drug trials a retrospective cohort study of applications to the Danish Medicines Agency
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2010.03755.x Methodological characteristics of academic clinical drug trials a retrospective cohort study of applications to the Danish
More informationStatistics in Medicine Reporting of Subgroup Analyses in Clinical Trials
T h e n e w e ng l a nd j o u r na l o f m e dic i n e s p e c i a l r e p o r t Statistics in Medicine Reporting of Subgroup Analyses in Clinical Trials Rui Wang, M.S., Stephen W. Lagakos, Ph.D., James
More informationTechnology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303
Teriflunomide for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303 NICE 2018. All rights reserved. Subject to Notice of
More informationDisclosures and Acknowledgments
214 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Dallas, Texas DX1 Disability Progression in Multiple Sclerosis
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationConflicts of Interest in Clinical Studies
Conflicts of Interest in Clinical Studies Steven Joffe, MD, MPH Assistant Professor of Pediatrics steven_joffe@dfci.harvard.edu ASGCT Clinical Trials Training Course May 18, 2010 1 Disclosure Information
More informationDimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials
Dimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore, Maryland Abstract Treatment options for multiple
More informationThe Promise of Novel Clinical Trial Designs. Michael Parides, Ph.D. Mount Sinai School of Medicine
The Promise of Novel Clinical Trial Designs Michael Parides, Ph.D. Mount Sinai School of Medicine Productivity New Drug Approvals (NMEs) R&D Spending (billions) $12 $13 $13 $15 $49 $38 $39 $43 $30 $32
More informationNational Horizon Scanning Centre. Cladribine (Movectro) for multiple sclerosis; relapsing-remitting. April 2008
Cladribine (Movectro) for multiple sclerosis; relapsing-remitting April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationField trial with veterinary vaccine
١ Field trial with veterinary vaccine Saeedeh Forghani,, M.D. Clinical Trial and Ethics Department Human Health Management Deputy of Quality Assurance 89/4/2 ٢ ٣ Introduction: The efficacy and safety shall
More informationSponsor- vs. investigator-initiated clinical intervention research. Jan P Vandenbroucke Leiden University Medical Center
Sponsor- vs. investigator-initiated clinical intervention research Jan P Vandenbroucke Leiden University Medical Center Outline The problem with industry-sponsored research The problem with investigator-initiated
More informationEvidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis
Evidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis Produced by CRD and CHE Technology Assessment Group Authors Gill Norman, Research Fellow, CRD Stephen
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 3 - Essential principle 3.2 Treatment allocation (randomization) 3.3 Study quality control 3.4 Trial monitoring: Interim decision and group sequential
More informationAlternative Trial Designs
Alternative Trial Designs STATS 773: DESIGN AND ANALYSIS OF CLINICAL TRIALS Dr Yannan Jiang Department of Statistics May 16 th 01, Wednesday, 08:30-10:00 Standard Design of RCT Individual subject is randomly
More informationIncluding Real World Evidence (RWE) in network meta-analysis
Including Real World Evidence (RWE) in network meta-analysis David Jenkins, Reynaldo Martina, Sylwia Bujkiewicz, Pascale Dequen & Keith Abrams Department of Health Sciences, Background GetReal is a three-year
More informationAn Introduction to Flexible Adaptive Designs
An Introduction to Flexible Adaptive Designs Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical Center David Geffen School of Medicine at UCLA Los Angeles Biomedical Research
More informationIntroduction to Adaptive Design Roger J. Lewis, MD, PhD
Introduction to Adaptive Design Roger J. Lewis, MD, PhD Financial Disclosures Berry Consultants, LLC Multiple clients U01 Support from National Institutes of Health/NINDS Food and Drug Administration AspenBio
More informationA biomarker-based adaptive two-stage randomizedphase II study design
A biomarker-based adaptive two-stage randomizedphase II study design Virginia L. Filiaci, PhD Mark F. Brady, PhD Gynecologic Oncology Group Statistical and Data Center Trial Design Setting Phase II Putative
More informationEvidence-Based Medicine What it Is. Critical Analysis of Clinical Trials Assessing Therapeutic Value
Critical Analysis of Clinical Trials Assessing Therapeutic Value Douglas S. Goodin, M.D. Professor of Neurology, UCSF Any astronomer can predict just where every star will be at half past eleven tonight.
More informationFDA Perspective on Clinical Trial Design for Rare Diseases
FDA Perspective on Clinical Trial Design for Rare Diseases American Statistical Association Biopharm Workshop Sept, 2018 Lucas Kempf, M.D. Associate Director Rare Diseases Program (acting) Office of New
More informationProof of Concept Vs Proof of Value
Evidence Requirements Supporting Critical Decisions in Pharmacotherapeutics: Proof of Concept Vs Proof of Value RG Peterson MD, PhD, MPH Executive Director Drug Safety and Effectiveness Network Canadian
More informationCladribine. Spirella Building, Letchworth, SG6 4ET reg charity no
Cladribine Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Cladribine Date of issue: February 2009 Contents Section Page 1. Introduction 1 2. How cladribine
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 3 - Essential principle Lecture schedule Nov 11: Special topics and designs 5.1 Design and analysis of crossover studies 5.2 Design and evaluation
More informationSTATISTICAL METHODS FOR ADAPTIVE DESIGNS
STATISTICAL METHODS FOR ADAPTIVE DESIGNS Workshop on flexible designs for diagnostic studies Göttingen, 6-7 November 2017 Tim Friede Department of Medical Statistics University Medical Center Göttingen
More informationDrug development and evaluation with small clinical Trials from the regulatory point of view
Drug development and evaluation with small clinical Trials from the regulatory point of view Harumasa Nakamura, M.D. Deputy Review Director Office of New Drug III Pharmaceuticals and Medical Devices Agency
More informationUse of modified intention to treat analysis in studies of direct oral anticoagulants and risk of selection bias.
Use of modified intention to treat analysis in studies of direct oral anticoagulants and risk of selection bias. Tristan Rainville, MD, a Madeleine Durand, MD, MSc, b Mikhael Laskine, MD, MSc, b a Centre
More informationSimplicity, Complexity and Modelling in Clinical Trials
Simplicity, Complexity and Modelling in Clinical Trials Stephen Senn (c) Stephen Senn 1 Acknowledgements This work is partly supported by the European Union s 7th Framework Programme for research, technological
More informationBiogen Idec Neurology Pipeline. Alfred Sandrock, MD, PhD SVP, Neurology Research & Development
Biogen Idec Neurology Pipeline Alfred Sandrock, MD, PhD SVP, Neurology Research & Development March 25, 2009 Robust Neurology Pipeline Neurology Multiple Sclerosis Discovery Pre-Clinical Phase 1 Phase
More informationEvidence Review Group s Report Template This template should be completed with reference to NICEs Guide to the Methods of Single Technology Appraisal
Evidence Review Group s Report Template This template should be completed with reference to NICEs Guide to the Methods of Single Technology Appraisal Title: Fingolimod for the treatment of relapsing remitting
More informationLeveraging Prognostic Baseline Variables in RCT. Precision in Randomized Trials
Leveraging Prognostic Baseline Variables to Gain Precision in Randomized Trials Michael Rosenblum Associate Professor of Biostatistics Johns Hopkins Bloomberg School of Public Health (JHBSPH) Joint work
More informationAn Overview of Bayesian Adaptive Clinical Trial Design
An Overview of Bayesian Adaptive Clinical Trial Design Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical Center David Geffen School of Medicine at UCLA Los Angeles Biomedical
More informationMycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: a preliminary study
Received: 20.6.2010 Accepted: 5.8.2010 Original Article Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: a preliminary study Masoud
More informationWhat s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance
Vol. 9, No. 2, February 2013 Happy Trials to You What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Reprinted from the Guide to Good Clinical Practice with permission of Thompson Publishing
More informationHow To Prepare An Informative And Thorough DSMB Report. Presenter: Amy Mhatre-Owens
How To Prepare An Informative And Thorough DSMB Report Presenter: Amy Mhatre-Owens Background Agenda Data and Safety Monitoring Board (DSMB) Report Structure Examples of useful charts, tables and listings
More informationPS02 Biomarker Analysis. Discussant. Sue-Jane Wang, Ph.D.
PS02 Biomarker Analysis Discussant Sue-Jane Wang, Ph.D. Associate Director, Adaptive Design, Pharmacogenomics/Phrmacogenetics Office of Biostatistics, Office of Translational Sciences, CDER CDER Statistics
More informationImplementing Current Regulatory Guidance: An Industry Perspective
Implementing Current Regulatory Guidance: An Industry Perspective European Statistical Meeting: Advances in the Treatment of Missing Data November 18, 2011 Brussels Mouna Akacha, Novartis Pharma AG Basel
More informationLEO in PSOriasis vulgaris, a Four weeks, vehicle controlled, efficacy A nd Saf ety Trial - the PSO-FAST trial
This document has been dov, nloaded from www.leo-pharma. com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationAlternative Study Designs and their Suitability for Paediatric Development
Alternative Study Designs and their Suitability for Paediatric Development Frank Pétavy Biostatistics and Methodology Support, Medicines Evaluation Division Workshop on the development of new medicinal
More informationFrancesca Rinaldi, Paola Perini, Matteo Atzori, Alice Favaretto, Dario Seppi, and Paolo Gallo. 1. Introduction. 2. Materials and Methods
Multiple Sclerosis International Volume 2015, Article ID 369348, 5 pages http://dx.doi.org/10.1155/2015/369348 Clinical Study Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression
More informationClinical trial design issues and options for study of rare diseases
Clinical trial design issues and options for study of rare diseases November 3, 2016 Jeffrey Krischer, PhD Rare Diseases Clinical Research Network Rare Diseases Clinical Research Network (RDCRN) is coordinated
More informationAPPRAISAL OF CLINICAL TRIALS. Su May Liew CEBM Oxford
APPRAISAL OF CLINICAL TRIALS Su May Liew CEBM Oxford Good study Experimental - RCT Fit question - PICO Passes appraisal - RAMMbo Minimises random error - statistics Why a trial? It may be better to do
More informationNatalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin. Multiple Sclerosis Treatment Update
Natalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin Complementarity-Determining Regions (CDRs) Multiple Sclerosis Treatment Update CDR grafted from murine Ab Human IgG 4 framework
More informationIncreasing value and reducing waste: Addressing inaccessible research
Increasing value and reducing waste: Addressing inaccessible research January 8, 2014 An-Wen Chan, MD DPhil Women s College Research Institute University of Toronto When I had to decide whether to have
More informationValuation of Lost Productivity (VOLP) questionnaire and outcomes. The paid work productivity loss obtained from the VOLP included three components: 1)
APPENDIX. ADDITIONAL METHODS AND RESULTS Valuation of Lost Productivity (VOLP) questionnaire and outcomes The paid work productivity loss obtained from the VOLP included three components: 1) absenteeism:
More informationAdaptive Model-Based Designs in Clinical Drug Development. Vlad Dragalin Global Biostatistics and Programming Wyeth Research
Adaptive Model-Based Designs in Clinical Drug Development Vlad Dragalin Global Biostatistics and Programming Wyeth Research 2007 Rutgers Biostatistics Day February 16, 2007 Outline Definition and general
More informationDesigns for Clinical Trials
Designs for Clinical Trials Design issues Research question Statistical optimality not enough! Use simulation models! Confounding Objective Control Statistics Design, Variables Ethics Variability Cost
More informationSESSION VI THE CHALLENGE OF NEW TREATMENTS THE PHARMA INDUSTRY
SESSION VI THE CHALLENGE OF NEW TREATMENTS THE PHARMA INDUSTRY Bruno C. Musch, MD PhD Baveno, Italy November 30th, 2013 DISCLOSURE OF INTEREST Dr.Musch is currently Medical Director in GENENTECH/Roche,
More informationNovel multiple testing procedures for structured study objectives and families of hypotheses a case study
Novel multiple testing procedures for structured study objectives and families of hypotheses a case study Guenther Mueller-Velten Novartis Pharma AG EMA Workshop on Multiplicity Issues in Clinical Trials
More informationSystematic Reviews: How Accurate Are They and Can We Do Better?
Systematic Reviews: How Accurate Are They and Can We Do Better? Authors: Gerald Borok, PhD, MPH Todd Feinman, MD Iris Tam, PharmD Gerald M. Borok, PhD, MPH Senior Director, Client Solutions Doctor Evidence,
More informationPage 78
A Case Study for Radiation Therapy Dose Finding Utilizing Bayesian Sequential Trial Design Author s Details: (1) Fuyu Song and (2)(3) Shein-Chung Chow 1 Peking University Clinical Research Institute, Peking
More informationHow to reduce bias in the estimates of count data regression? Ashwini Joshi Sumit Singh PhUSE 2015, Vienna
How to reduce bias in the estimates of count data regression? Ashwini Joshi Sumit Singh PhUSE 2015, Vienna Precision Problem more less more bias less 2 Agenda Count Data Poisson Regression Maximum Likelihood
More informationwarwick.ac.uk/lib-publications
Original citation: Mistry, Pankai, Dunn, Janet A. and Marshall, A. (Andrea). (2017) A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials
More informationPRIORITIZATION OF CLINICAL RESEARCH SILVIO GARATTINI. Milan 30 th November 2007
PRIORITIZATION OF CLINICAL RESEARCH SILVIO GARATTINI Milan 30 th November 2007 PERSPECTIVE FEASIBILITY KNOWLEDGE INDUSTRY NHS PATIENTS STATE OF THE ART INFRASTRUCTURE TEAMS INPUT INSTITUTIONS SCIENTIFIC
More informationValue Assessment: Building Payercentric value propositions to inform decision-making
Value Assessment: Building Payercentric value propositions to inform decision-making Aris Angelis and Panos Kanavos Medical Technology Research Group, LSE Health Advance-HTA dissemination workshop, Santiago,
More informationStatistical Considerations
Version 1.3 Effective date: 21 May 2012 Author: Approved by: Dr Ranjit Lall, Research Fellow Statistician Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.3 21 May 2012 Version
More informationThe BEST Platform. A Modular Early-Phase Platform for Seamless Dose Finding and Cohort Expansion Laiya Consulting, Inc. 2018
The BEST Platform A Modular Early-Phase Platform for Seamless Dose Finding and Cohort Expansion Laiya Consulting, Inc. 2018 Introduction The Bayesian early-phase seamless transformation (BEST) platform
More informationInformation for clinical researchers on transparency of clinical trial reporting
Information for clinical researchers on transparency of clinical trial reporting This document has been produced by leading UK healthcare organisations including the medical Royal Colleges and senior representatives
More informationDesigning Generalizable Trials: Why Inclusivity Matters. Estelle Russek-Cohen, PhD U.S. Food and Drug Administration Center for Biologics
Designing Generalizable Trials: Why Inclusivity Matters Estelle Russek-Cohen, PhD U.S. Food and Drug Administration Center for Biologics 1 Disclaimer The thoughts expressed are my own and should not be
More informationTrial-design in biosimilar research: Equivalence or non-inferiority design
Trial-design in biosimilar research: Equivalence or non-inferiority design Prof. Kit C.B. Roes Professor of Clinical Trial Methodology Advisor to MEB-CBG Overview The place(s) of the clinical efficacy
More informationGEN-003. Positive Phase 2b Clinical Efficacy Results. Immunotherapy Candidate for Genital Herpes. 12-Month Top-line Results
GEN-003 Positive Phase 2b Clinical Efficacy Results Immunotherapy Candidate for Genital Herpes 12-Month Top-line Results Disclaimer This presentation contains forward-looking statements that are within
More informationDFG. Proposal Preparation Instructions. Clinical Trials Draft Proposals. DFG form /14 page 1 of 8
form 17.03 10/14 page 1 of 8 Proposal Preparation Instructions Clinical Trials Draft Proposals form 17.03 10/14 page 2 of 8 Please write your proposal in English and use the Draft Proposal Template ( form
More informationA reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies
Sully et al. Trials 2013, 14:166 TRIALS RESEARCH Open Access A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies Ben G O
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 10 Apr 2019 10:29:54 GMT) CTRI Number Last Modified On 24/08/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More information2018 ECTRIMS Data Review Call. October 2018
2018 ECTRIMS Data Review Call October 2018 TG Therapeutics Michael S. Weiss, CEO Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationDisease modifying therapies in multiple sclerosis
Special Article Disease modifying therapies in multiple sclerosis Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical
More informationEfficacy of experimental treatments compared with standard treatments in non-inferiority trials: A meta-analysis of randomized controlled trials.
Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: A meta-analysis of randomized controlled trials. Darius Soonawala, Rutger A Middelburg, Matthias Egger,
More informationGetting Published: What Journal Editors Really Want
Getting Published: What Journal Editors Really Want Edward Abraham M.D. Professor and Chair, Department of Medicine University of Alabama at Birmingham Presenter Disclosures Edward Abraham M.D. Personal
More informationINNOVATIVE STATISTICAL DESIGN & ANALYSIS IN PD
INNOVATIVE STATISTICAL DESIGN & ANALYSIS IN PD Christopher S. Coffey Department of Biostatistics University of Iowa February 22, 2017 OVERVIEW The traditional approach to clinical trials tends to be large,
More informationSources of Bias in Metaanalysis
Sources of Bias in Metaanalysis of RCTs Tarek A. Hammad, MD, PhD, MSc, MS, FISPE Executive Director, Epidemiology, Merck Research Laboratories Former Deputy Director of Epidemiology, OPE, OSE, CDER, FDA
More informationThe Effect of an Unplanned Sample Size Re-Estimation on the Type I Error Rate
The Effect of an Unplanned Sample Size Re-Estimation on the Type I Error Rate Leslie A. McClure 1, Jeff M. Szychowski 1, Oscar Benavente 2, Robert G. Hart 3 & Christopher S. Coffey 4 1 Department of Biostatistics,
More informationComments from: 1. General comments
SUBMISSION OF COMMENTS ON < Draft Implementing technical guidance - List of fields for result-related information to be submitted to the 'EudraCT' clinical trials database, and to be made public, in accordance
More informationJennifer Pulley (Statistical Scientist)
A bioequivalence study design in Immunology which includes the option for sample size reestimation (SSR) at the Interim Analysis Jennifer Pulley (Statistical Scientist) Overview Study design Interactions
More informationMedia Release. Basel, 14 June 2018
Media Release Basel, 14 June 2018 Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive
More informationReview of week-24 results
Review of week-24 results GNC-003: an international, double-blind, randomized, placebo-controlled phase IIb trial to assess the efficacy, safety and pharmacokinetics of in patients with relapsing remitting
More information